Skip to main content

Table 5 Major series reporting surgical management of hepatic metastases from gynaecological malignancies

From: Surgical management of lung, liver and brain metastases from gynecological cancers: a literature review

First Author Year of Publication Number of patients Primary vs Recurrent Disease Primary Site Median overall survival (from time of liver resection unless otherwise stated) Factors associated with longest survival
Kolev [91] 2014 27 Recurrent Ovary 12 months
(2–190)
Interval from primary surgery of >24 months (P = 0.044)
Secondary cytoreduction to <1 cm (P = 0.014)
Neumann [82] 2012 41 Primary Ovary R0 – 42 months
R1 – 4 months
R2 – 6 months
Post operative residual tumour mass
Roh [77] 2011 18 Recurrent Ovary 38 months
(3–78)
Less abdominal than pelvic disease (38 vs 11 months, P = 0.032)
Optimal cytoreduction (40 vs 9 months, P = 0.0004)
Negative margin status of hepatic resection
(40 vs (months, P = 0.0196
Kamel [92] 2011 52 Primary Ovary 53 months
5-year survival 41 %
Not reported
Knowles [93] 2010 5 Recurrent Endometrioid (Ovarian or Endometrial) Median OS not reported
DFS range 8–66 months
Not reported
Lim [75] 2009 14 Primary Ovary 5-year PFS by Stage:
- IIIC – 25 %
- IV – 23 %
5-year OS by Stage:
- IIIC – 55 %
- IV – 51 %
Not reported
Loizzi [94] 2005 29 Primary (Group 1) – 8
1st Recurrence (Group 2) – 10
2nd recurrence (Group 3) – 11
Ovary Median survival from time of liver metastasis diagnosis:
Group 1 – 19 months
Group 2 – 24 months
Group 3 – 10 months
Cell type
Performance status
Number of hepatic lesions
Presence of other sites of disease at time of diagnosis of hepatic metastasis
Platinum based chemotherapy
Weitz [76] 2005 19 Recurrent Ovary – 63.2 %
Endometrium – 21.1 %
Cervix – 10.5 %
Fallopian tube – 5.2 %
Reproductive tract tumours (note – included testicular cancer pts, but no difference between ovary and testicular survival)
Median cancer specific survival reproductive tract primary – 115 months
Ovary - 3 year recurrence free survival 58 %
Primary tumour type
Length of disease free interval from primary tumour
Yoon [95] 2003 24 Recurrent Ovary
Fallopian tube
62 months
(6–94)
No significant prognostic factors for OS identified on univariate analysis
Merideth [89] 2003 26 Recurrent Ovary Overall median disease-related survival 26.3 months >12 months since original diagnosis (27.3 vs 5.7 months, P = 0.004)
≤1 cm residual disease (27.3 vs 8.6 months, P = 0.031)
Fan [96] 2001 18   Ovary – immature teratoma 3-year survival – 77.8 %
5-year survival – 55.6 %
10-year survival – 38.9 %
Not reported
Naik [97] 2000 37 Primary Ovary 11 months
2-year survival 23 %
5-year survival 9 %
Optimal surgery with residual <2 cm (P = 0.0029) or <1 cm (P = 0.0086)
Bristow [81] 1999 37 Primary Ovary Optimal extrahepatic and hepatic resection – 50.1 months
Optimal extrahepatic resection with residual hepatic tumour – 27.0 months
Suboptimal with residual extrahepatic and heaptic tumour – 7.6 months
Optimal extrahepatic resection (P = 0.0001)
Elias [84] 1998 6 Not stated Gynecologic 5-year survival – 45 % Not reported
Chi [71] 1997 12 Recurrent Ovary – 58 %
Cervix – 17 %
Endometrium – 17 %
Fallopian tube – 1 8 %
27 months
(Median f/up 25 months, range 8–94 months)
Not reported
  1. OS overall survival, DFS disease-free survival, PFS progression-free survival